Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

167.29USD
18 Aug 2017
Change (% chg)

$-0.52 (-0.31%)
Prev Close
$167.81
Open
$167.37
Day's High
$168.43
Day's Low
$166.52
Volume
1,741,936
Avg. Vol
3,111,267
52-wk High
$184.21
52-wk Low
$133.64

Latest Key Developments (Source: Significant Developments)

Temasek Holdings takes stake in JPMorgan, Biogen, Celgene
Monday, 14 Aug 2017 09:05am EDT 

Aug 14 (Reuters) - Temasek Holdings (Private) Ltd::Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares.Temasek Holdings takes share stake in Biogen Inc of 95,226 shares - SEC filing.Temasek Holdings takes share stake of 206,187 shares in Celgene Corp.Temasek Holdings takes share stake of 151,310 shares in Amgen Inc.Temasek Holdings ups share stake in Royal Dutch Shell Plc to 2.4 million class B sponsored ADR shares from 408,543 class B sponsored ADR shares.Temasek Holdings ups share stake in Regeneron Pharmaceuticals by 40.5 percent to 177,553 shares.Temasek Holdings : change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017.  Full Article

Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Cytokinetics Inc ::Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics inc - ‍company is eligible to earn $10 million milestone payment from amgen upon first patient dosing in Japan in phase 3 outcomes trial​.Cytokinetics inc - ‍phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure has met its pharmacokinetic primary endpoint​.Cytokinetics inc - ‍phase 2 clinical trial demonstrated statistically significant improvements in systolic ejection time (set), a secondary endpoint​.Cytokinetics inc - ‍cytokinetics is eligible to earn a $10 million milestone payment from amgen upon first dosing of a patient in Japan in Galactic-Hf​.  Full Article

Amgen submits supplemental biologics license application for Prolia in glucocorticoid-induced osteoporosis
Monday, 31 Jul 2017 09:10am EDT 

July 31 (Reuters) - Amgen Inc :Amgen submits supplemental biologics license application for Prolia® (denosumab) in glucocorticoid-induced osteoporosis.Amgen Inc - ‍Submission of a supplemental biologics license application to U.S. Food and Drug Administration for Prolia​.Amgen - Results from phase 3 study in SBLA submission showed treatment with Prolia for 12 months led to statistically significant greater gains in BMD.Amgen- ‍SBLA based on a phase 3 study evaluating safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment​.Amgen Inc - Adverse events and serious adverse events (SAES) were similar across treatment groups and consistent with known safety profile of Prolia.  Full Article

Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA
Monday, 31 Jul 2017 09:00am EDT 

July 31 (Reuters) - Amgen Inc :Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration.Amgen - Co and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is second to be submitted for FDA approval​.  Full Article

FDA grants priority review for Amgen's supplemental biologics license application for Repatha
Thursday, 27 Jul 2017 05:50pm EDT 

July 27 (Reuters) - Amgen Inc :FDA grants priority review for Amgen's supplemental biologics license application for Repatha® (evolocumab) to include data on reducing risk of cardiovascular events.Amgen Inc - ‍FDA has set a prescription drug user fee act (PDUFA) action date of Dec. 2, 2017. for Repatha​.Amgen Inc - Second application seeking to expand lipid-lowering indication to include additional patient populations studied was also accepted by FDA.  Full Article

Amgen Q2 GAAP shr $2.91
Tuesday, 25 Jul 2017 04:01pm EDT 

July 25 (Reuters) - Amgen Inc :Amgen reports second quarter 2017 financial results.Q2 revenue $5.8 billion versus i/b/e/s view $5.67 billion.Q2 non-gaap earnings per share $3.27.Q2 gaap earnings per share $2.91.Sees fy 2017 revenue $22.5 billion to $23 billion.Q2 earnings per share view $3.11 -- Thomson Reuters I/B/E/S.Sees q3 2017 non-gaap earnings per share $12.15 to $12.65.Sees fy 2017 gaap earnings per share $10.79 to $11.37.  Full Article

Amgen Q2 GAAP shr $2.91
Tuesday, 25 Jul 2017 04:01pm EDT 

July 25 (Reuters) - Amgen Inc :Q2 gaap earnings per share $2.91; q2 non-gaap earnings per share $3.27; q2 total revenue $5.81 billion versus $5.69 billion.Amgen - 2017 eps outlook increased to $10.79-$11.37 on gaap basis, $12.15-$12.65 on non-gaap basis; 2017 revenue outlook revised to $22.5 billion-$23 billion.Q2 earnings per share view $3.11, revenue view $5.67 billion -- Thomson Reuters I/B/E/S.Says expects 2017 capital expenditures to be approximately $700 million.Fy2017 earnings per share view $12.48, revenue view $22.69 billion -- Thomson Reuters I/B/E/S.  Full Article

Amgen says FDA accepts biologics license application for Aimovig
Thursday, 20 Jul 2017 04:30pm EDT 

July 20 (Reuters) - Amgen Inc :FDA accepts biologics license application for Aimovig™ (erenumab).Amgen Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of May 17, 2018..Amgen Inc - Aimovig will be jointly commercialized in U.S. by Amgen and Novartis..  Full Article

Amgen and Array BioPharma announce preclinical license and collaboration agreement
Tuesday, 18 Jul 2017 08:00am EDT 

July 18 (Reuters) - Array BioPharma Inc :Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation.Array BioPharma - under terms of agreement, Amgen and Array will collaborate on preclinical development with Array leading medicinal chemistry work.Array BioPharma Inc - ‍Amgen is responsible for clinical development and commercialization​.Array BioPharma - in exchange for exclusive rights to Array's preclinical program, Amgen will make upfront and milestone payments.Array BioPharma - Amgen will also pay royalties on sales of resulting therapies.  Full Article

Amgen submits regulatory applications in US, Europe
Friday, 14 Jul 2017 09:00am EDT 

July 14 (Reuters) - Amgen Inc ::Amgen submits regulatory applications in US and Europe to include overall survival data in kyprolis (carfilzomib) label.Amgen - data showed kyprolis and dexamethasone reduced risk of death by 21 percent and increased overall survival by 7.6 months versus velcade and dexamethasone​.Amgen - ‍announced variation to marketing application to EMA to include OS data from phase 3 head-to-head endeavor trial in product info for kyprolis​.Says ‍adverse events observed in this updated analysis were consistent with those previously reported for endeavor​.Amgen - submission of SNDA to FDA, variation to marketing application to EMA to include overall survival data from phase 3 kyprolis​ trial.  Full Article

BRIEF-Amgen and Humana partner for improved health outcomes

* Amgen and Humana partner for improved health outcomes and efficiency Source text for Eikon: Further company coverage: